Another study, conducted by Xie et al., indicated that NanoCAR-T cells engineered to secrete anti-CD47 nanobodies (variable domain of heavy chain-only antibodies or VHH) were able to inhibit tumor growth, while avoiding toxicity encountered with systemic anti-CD47 therapy. Here, CD47 is linked to neoplasm.